Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Cullgen Seeded with $15 Million from GNI, a Japan-China Biopharma

publication date: Mar 1, 2018

Cullgen, a US-Japan-China small-molecule drug startup, announced a Seed Financing of up to $15 million from GNI Group. Cullgen plans to develop drugs based on its ubiquitin-mediated protein degradation technology, which the company says will address previously undruggable targets. GNI is headed by Ying Luo, PhD, the founder of Shanghai Genomics, a company that was acquired by GNI. GNI has operations in Tokyo, Shanghai and Beijing. Dr. Luo will serve as President and CEO of Cullgen, which will initially focus on oncology and expand into inflammatory and autoimmune diseases. More details....

Stock Symbol: (TOKYO: 2160)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital